Cost Barrier for Injectable Treatments Clinical data reveals that current regimens lack sustainability due to strong side effects: Gastrointestinal complications: Side Effects of Some Current Weight Loss Treatments (Forbes) Severe complications include acute pancreatitis, kidney injury, gallbladder injury, diabetic retinopathy, and gastroparesis
This is not just a carbohydrate source
Compounded semaglutide and tirzepatide are not approved by the FDA and have not been evaluated for safety, effectiveness, or quality by the FDA
In contrast, drugs such as Wegovy and Zepbound have shown an ability to produce weight loss almost to a similar extent as bariatric surgery
Advantages: - No needles required - Familiar pill format Considerations: - Must be taken under strict conditions (empty stomach, timing requirements) - Lower bioavailability than injectable form - Currently only available as brand-name (no compounded version) - May require higher doses for comparable efficacy For most patients seeking meaningful weight loss results, injectable GLP-1 medications currently offer stronger clinical evidence and more predictable outcomes
